 SAN CARLOS, Calif., April 27, 2022 GLOBE NEWSWIRE -- Iovance Biotherapeutics, Inc. NASDAQ: IOVA, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients with metastatic melanoma will be highlighted at the upcoming 2022 ASCO Annual Meeting, to be held June 3-7, 2022 at McCormick Place in Chicago, Ill. and online. The abstract title is as follows: 